Regulation and consequences of LRRK2 phosphorylation, a path to Parkinson’s disease therapy and diagnostics

Project Information

RECOLOR

Grant agreement ID: 659183

DOI

10.3030/659183

Project closed

EC signature date 21 April 2015

Start date 1 June 2015

End date 31 May 2017

Funded under

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Total cost

€ 185 076,00

EU contribution

€ 185 076,00

Coordinated by

UNIVERSITE DE LILLE
France

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (3)

LRRK2 detection in human biofluids: potential use as a Parkinson's disease biomarker?

Author(s): Jean-Marc Taymans, Eugénie Mutez, Matthieu Drouyer, William Sibran, Marie-Christine Chartier-Harlin
Published in: Biochemical Society Transactions, Issue 45/1, 2017, Page(s) 207-212, ISSN 0300-5127
Publisher: Portland Press, Ltd.
DOI: 10.1042/BST20160334

LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?

Author(s): Jean-Marc Taymans, Elisa Greggio
Published in: Current Neuropharmacology, Issue 14/3, 2016, Page(s) 214-225, ISSN 1570-159X
Publisher: Bentham Science Publishers
DOI: 10.2174/1570159X13666151030102847

Cryo-EM analysis of homodimeric full-length LRRK2 and LRRK1 protein complexes

Author(s): Kushal Sejwal, Mohamed Chami, Hervé Rémigy, Renée Vancraenenbroeck, William Sibran, Rosmarie Sütterlin, Paul Baumgartner, Robert McLeod, Marie-Christine Chartier-Harlin, Veerle Baekelandt, Henning Stahlberg, Jean-Marc Taymans
Published in: Scientific Reports, Issue 7/1, 2017, Page(s) 8667, ISSN 2045-2322
Publisher: Nature Publishing Group
DOI: 10.1038/s41598-017-09126-z